Anbio Biotechnology Class A Ordinary Shares (NNNN)

FairStock Score: 35/100 — MIXED

Key Financials

Strengths

• High return on equity of 27.1% demonstrating efficient capital deployment
• Altman Z-Score of 8413.7 confirms minimal bankruptcy risk and strong solvency

Concerns

• Trades significantly above Graham Number ($2) with negative 1734% margin of safety—limited downside protection
• Weak Piotroski F-Score of 2/9 suggests deteriorating financial quality across multiple dimensions

AI Analysis

Anbio Biotechnology Class A Ordinary Shares is a micro-cap healthcare company valued at $1.2 billion. Revenue stands at $9 million. From a quality standpoint, Anbio shows weak Piotroski F-Score of 2/9 signaling deteriorating fundamentals and Altman Z-Score of 8413.7 confirms fortress-level solvency. On valuation, the stock is commanding a steep 179.6x multiple, with trades far above its Graham Number ($2) with no margin of safety. Our composite FairStock Score of 35/100 reflects below-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

At 180x earnings, any growth disappointment triggers rapid multiple compression—a 20% earnings miss plus multiple contraction to 20x implies 40%+ downside. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer